1/84
Looks like no tags are added yet.
Anabolic Steroids
-androgen receptor agonists
-effects such as weight gain and increased muscle mass
5alpha-reductase
converts testosterone to DHT
Aromatase
converts testosterone to estradiol
Cholesterol
precursor to steroids
Suppress
Elevated androgens _____________________ the HPG axis
Androgens
Effects:
-growth of penis, scrotum, larynx, skeleton
-development of facial, pubic, and axillary hair
-darkening of skin
-increased muscle mass/strength
-increased RBC production
-libido, fertility, bone mineral density
Androgens
MOA:
-dissociate from SHBG
-enters cells and binds to cytosolic receptors
-hormone-receptor complex dimerizes and enters nucleus
-modulates gene expression
Androgen Replacement Therapy
for hypogonadism and hypopituitarysm prior to adolescene
Androgen Replacement Therapy
Indications:
-gynecologic disorders
-reverse protin loss
-anemia
-osteoporossis
-growth stimulation in delayed puberty
-female to male transsexual gender dysphoria
Danazol
weak androgen with anti-estrogen activity that is used for endometriosis
Androgen Replacement Therapy
Off-label Uses:
-reduce post-partum (with estrogen)
-endometriosis
-Post-menopausal elimination of bleeding and enhancing lipido
-premenopausal in breast tumor chemotherapy
Oral
What Preparation:
-methyltestosterone
-fluoxymesterone
Parenteral
What Preparation:
-testosterone enanthate
-testosterone cypionate
-testosterone propionate
-testosterone undecanoate
Testosterone Propionate
What formulation of Testosterone is NOT recommended due to short duration of action
Testosterone Undecanoate
What formulation of Testosterone is NOT recommended due to association with liver tumors?
-methyltestosterone
-fluoxymesterone
-patient friendly administration
-flexible dosing
-immediate discontinuation
-ineffective androgen effects
-negative lipid effects
-high risk of hepatic adverse effects
Testosterone Undecanoate
-"rollercoaster" pharmacokinetics
-fluctuations in mood, libido
-site rxns
-pulmonary oil microembolism rxn
-higher CV risk than topical products
-good safety porfile
-injections every 10 weeks
-testosterone enanthate
-testosterone cypionate
-"rollercoaster" pharmacokinetics
-fluctuations in mood, libido
-site rxns
-pulmonary oil microembolism rxn
-higher CV risk than topical products
-good safety profile
-inexpesive
-injections every 2-4 weeks
Gels/Solutions
What preparation of testosterone:
-cross exposure of product
-apply deoderant first
-expensive
-daily administration
-higher potency and small surface area
Pellet
What preparation of testosterone:
-unpredictable pharmacokinetics
-local site reactions
-difficult dosing regimen
-requirement of incision
Testosterone Undecanoate
available only through a restricted program called the Aveed(R) REMS Program due to the risk of serious pulmonary oil microembolism (POME) reactions (urge to cough, dyspnea, throat tightening, chest pain, dizziness, syncope) and potentially life-threatening anaphylaxis
Testosterone Replacement Therapy
CIs:
-breast or prostate cancer
-BPH
-pregnancy
BP increases
BBW for testosterone undecanoate and SC testosterone encanthate
Testosterone Replacement Therapy
-can increase BP
-can cause fluid retention and heart failure
-dont use in men who have experienced an MI or stroke within the past 6 months
-may worsen sleep apnea
Testosterone Replacement Therapy
Adverse effects
• Sodium retention: Edema, weight gain
• Acne, gynecomastia, hair loss/balding, infertility (azoospermia and decreased testicular size)
• Worsened sleep apnea, elevated blood pressure, decrease total cholesterol and HDL
• Oral: hepatotoxicity
• Parenteral: polycythemia
• Topical: site reactions
-Warfarin (increased bleeding)
-Paclitaxel (toxicity)
-Bupropion (lowered seizure threshold)
Drug interactions with Testosterone replacement therapy
3 Month
Testosterone therapies in any route/dose should have a __________________ trial before determining response
GnRH Agonists
-antiandrogen option for advaned prostatic carcinoma
-goserelin, nafarelin, leuprolide
Steroid Synthesis Inhibitors
-antiadrogen option for advaned prostatic carcinoma
-ketoconazole, spironolactone, abiraterone, finasteride, dutasteride
Androgen Receptor Inhibitors
-antiadrogen option for advaned prostatic carcinoma
-cyproterone, flutamide, bicalutamide, nilutamide, enzalutamide, spironolactone, apalutamide, and darolutamide
Leoprolide
-produces an initial increase in LH and FSH which leads to a transient increase testosterone and dihydrotestosterone (in males) and estrone and estradione (in premenopausal females).
-receptor inhibitor
-suppresses ovarian and testicular steroidogenesis
• Dopamine exerts a proerectogenic effect
• α2-adrenergic stimulation (makes penis flaccid)
Integration of external stimuli via medial pre-optic area of the hypothalamus
• Inhibitory sympathetic neurons (T11-L2)
• Proerectogenic parasympathetic neurons (S2-S4)
• Proerectogenic somatic neurons (S2-S4)
nerve impulses travel to the penis via what?
Nitric Oxide and cGMP
Androgen receptors in the penile arterial endothelium may increase cavernosal levels of ______________________ and __________________
Flaccid
arterial flow into and venous outflow from the corpora are balanced
Erectile Phase
-arterial blood flow increases, and blood fills the sinusoids within the corpora
-• Swelling and elongation
• Prolongation or sustainment of erection occurs by
venous outflow occlusion from the corpora
Two; One
How many:
_________ corpora cavernosa & ___________ corpus spongiosum
Acetylcholine (ACh)
what neurotransmitter enhances nitric oxide production?
Prostaglandin E
enhances the activity of adenyl cyclase resulting in smooth muscle relaxation via vasodilation and enhanced arterial blood flow into the corpora
-Anti-androgens
-5alpha-reductase inhibitors
-Anti-hypertensives
-Anti-arrhythmics
-Psychotropics
Medications that can contribute to ED
-Smoking
-Diabetes
-Hypertension
-Obesity
most common preventable ED risk factors
Phosphodiesterase-5 inhibitors (PDE5Is)
first line for ED with complete cardio risk assessment
Alprostadil
what drug is considered if PDE5is are ineffective or cannot be used?
Coronary Artery Disease
ED and ___________________ frequently coexist
Cardiovascular Status
It is prudent to evaluate a patient's ____________________ before initiating treatment of ED with a PDE5 inhibitor
-Testosterone Replacement
-Vaccuum Erection Devices
-Surgery
if PDE-5is and Alprostadil dont work, what are your other options?
Phosphodiesterase-5 inhibitors (PDE5Is)
-Avanafil
-Sildenafil
-Tadalafil
-Vardenafil
Phosphodiesterase-5 inhibitors (PDE5Is)
"-afil"
Phosphodiesterase-5 inhibitors (PDE5Is)
Indications:
• Erectile dysfunction, pulmonary arterial hypertension
• Off label: Raynaud phenomenon
• 1st line therapy due to onset of action, efficacy,
discretion with use, and level of invasiveness
Reversible
Phosphodiesterase-5 inhibitors (PDE5Is) work via competitve __________________ inhibition
Phosphodiesterase-5 inhibitors (PDE5Is)
- Decreases degradation of cGMP to enhance smooth muscle relaxation and inflow of blood into corpus
cavernosum
• Also inhibit phosphodiesterase in non-genital tissues
Sildenafil
-PDE5 and PDE-6 inhibition
-absorption impaired by fatty meals
-take 30-60 min before sexual activity
-take on empty stomach
-do not use in severe renal/hepatic disease
Vardenafil
-PDE5 and minimal PDE-6 inhibition
-absorption impaired by fatty meals
-take 30-60 min before sexual activity
-take on empty stomach
-do not use in severe renal/hepatic disease
Tadalafil
-PDE5 and PDE11 inhibtion
-take 2 hours before sexual activity
-slower onset
-do not use in severe renal/hepatic disease
Avanafil
-PDE5, minimal PDE6 and 11 inhibition
-take 30-60 min before sexual activity
-do not use in severe renal/hepatic disease
PDE-6
-Phosphotiesterase isoenzyme found in rods and cones of the eye.
-Drug inhibition assoc with blurred vision and cyanopsia
PDE-11
-Phosphotiesterase isoenzyme found in striated muscle
-inhibtiion assoc with myalgia and muscle pain
Tadalafil
which PDE5i has the msot inhibitory action of PDE-11
Phosphodiesterase-5 inhibitors (PDE5Is)
Contraindications:
• Regular or intermittent concurrent use of organic nitrates in any form
• Concomitant use of riociguat
Phosphodiesterase-5 inhibitors (PDE5Is)
Drug interactions:
• Nitrates
• Riociguat
• Antihypertensives
• Alpha antagonists
• CYP3A4 inhibitors
• Vardenafil + class I or III
antiarrhythmics
Phosphodiesterase-5 inhibitors (PDE5Is)
Adverse effects
• Common: headache, facial flushing,
dyspepsia, nasal congestion, dizziness
• Priapism (direct patient to ED)
• Serious: Non-arteritic anterior ischemic
optic neuropathy, hearing loss
Hypotension
adverse effect assoc with both Sildenafil and Vardenafil
Visual Disturbances
Adverse effect assoc with Sildenafil, Vardenafil, and Avanafil
Alprostadil
-PDE5i
• Indication: Erectile dysfunction
• Off label: Raynaud phenomenon
Alprostadil
• Prostaglandin E1
• Stimulates adenyl cyclase to increase cAMP, which ↓ intracellular calcium concentration and causes smooth muscle relaxation
• ↑ blood flow to and blood filling of the corpora
Alprostadil
Contraindications
• Priapism predisposing conditions (hyperviscosity syndromes like sickle cell anemia or trait, multiple myeloma, leukemia)
• Anatomical deformation or fibrotic conditions of the penis (angulation, cavernosal fibrosis, or Peyronie disease)
• Penile implants
Alprostadil
Contraindications
• Priapism predisposing conditions
(hyperviscosity syndromes like sickle cell
anemia or trait, multiple myeloma, leukemia)
• Anatomical deformation or fibrotic conditions
of the penis (angulation, cavernosal fibrosis,
or Peyronie disease)
• Penile implants
Intraurethral Injection
-preparation of Alprostadil
-rapidly absorbed
-systemically absorbed and deactivated by first pass through lungs
Intraurethral Injection
-preparation of Alprostadil
CIs:
• Patients with urethral stricture or urethritis or curvature
• Men who are prone to venous thrombosis or who have a hyperviscosity syndrome (sickle cell anemia or trait, thrombocythemia, polycythemia, multiple myeloma) predisposing them to priapism
• Use in men for whom sexual activity is inadvisable
• Pregnancy in female partner without condom barrier
• Urethral injury, stricture, and difficulty voiding
• Urethral pain
• Vaginal pain, itching, burning in female sexual partner
• Rare: priapism, syncope, dizziness
AEs assoc with intraurethral injection of Alprostadil
• Local anesthesia
• Priapism not due to intracavernosal injection: penile aspiration
• Priapism secondary to intracavernosal injection: intracavernosal injection of sympathomimetic agent (phenylephrine)
Management of ischemic priapism
Vacuum Erection Device (VED)
• Cylinder attached to pump which creates negative pressure chamber
• Promotes arterial blood flow into corpora cavernosa
• Constriction bands or tension rings can be applied to the base of the penis to prolong erection
Vacuum Erection Device (VED)
-For pts with CIs or lack of response to PDE-5
inhibitors, or patient preference
• Combination therapy
• Nondescript; often discontinued by patients
-AEs: • Pain, bruising, injury, discoloration
• Penile curvature, sickle cell disease, history of priapism
• Caution in patients taking warfarin
CIs for Vacuum Erection Device (VED)
Hypogonadism
-deficiencies in gametogenesis and/or the secretion of gonadal hormones
• Low circulating levels of testosterone (defined as
Primary
_________________ Hypogonadism:
testicular failure
Secondary
_______________ Hypogonadism:
hypothalamic or pituitary dysfunction
Hypogonadism
Main Signs:
Decreased libido, erectile dysfunction, and loss of spontaneous morning erections
-decreased free Testosterone
Yohimbine
• Central α2-adrenergic antagonist; ↑ catecholamines and improves mood
• May have peripheral proerectogenic effects; may ↓ peripheral α adrenergic tone, causing
predominant cholinergic tone with a vasodilatory response
• AE include anxiety, insomnia, tachycardia, & HTN
Papaverine
• Nonspecific PDE5 inhibitor
-used as a vasodilator for arterial vasospasm
• Intracavernosal injection
Phentolamine
• Competitive nonselective α-adrenergic blocking agent
-used for extravasation of vasopressors and for settings of catecholamine excess
• Intracavernosal injection
Alprostadil
AEs:
• Local injection site reactions: penile pain, bruising, fibrosis leading to curvature
• Priapism, hypotension, dizziness
Alprostadil
Alprostadil
Contraindications
• Priapism predisposing conditions
(hyperviscosity syndromes like sickle cell
anemia or trait, multiple myeloma, leukemia)
• Anatomical deformation or fibrotic conditions
of the penis (angulation, cavernosal fibrosis,
or Peyronie disease)
• Penile implants
Alprostadil